Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa in metastatic urothelial carcinoma
NCT04501094Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2020
- Primary completion
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa in urothelial carcinoma (UC), sponsored by National Cancer Institute. Started Oct 2020; status: terminated.
02
Drugs
bintrafusp alfa
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04501094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04501094.